Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study

J Neuroimmunol. 2010 Oct 8;227(1-2):185-9. doi: 10.1016/j.jneuroim.2010.07.013. Epub 2010 Aug 21.

Abstract

We explore the safety, and therapeutic benefit of intrathecal injection of ex-vivo expanded autologous bone marrow derived mesenchymal stem cells (BM-MSCs) in 10 patients with advanced multiple sclerosis (MS). Patients were assessed at 3, 6 and 12 months. Assessment at 3-6 months revealed Expanded Disability Scale Score (EDSS) improvement in 5/7, stabilization in 1/7, and worsening in 1/7 patients. MRI at 3 months revealed new or enlarging lesions in 5/7 and Gadolinium (Gd+) enhancing lesions in 3/7 patients. Vision and low contrast sensitivity testing at 3 months showed improvement in 5/6 and worsening in 1/6 patients. Early results show hints of clinical but not radiological efficacy and evidence of safety with no serious adverse events.

Publication types

  • Clinical Trial, Phase I
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Bone Marrow Transplantation / adverse effects
  • Bone Marrow Transplantation / immunology*
  • Bone Marrow Transplantation / pathology
  • Cells, Cultured
  • Feasibility Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Injections, Spinal
  • Male
  • Mesenchymal Stem Cell Transplantation / adverse effects
  • Mesenchymal Stem Cell Transplantation / methods*
  • Middle Aged
  • Multiple Sclerosis / pathology*
  • Multiple Sclerosis / surgery*
  • Pilot Projects
  • Transplantation, Autologous
  • Treatment Outcome